Compare Kisqali vs. Ibrance
Head-to-head comparisons of medication uses, side effects, warnings, and more.
- Kisqali (ribociclib)Ibrance (palbociclib)
- Kisqali (ribociclib)Ibrance (palbociclib)
Summary of Kisqali vs. Ibrance
Summary for Cyclin-dependent kinase (CDK) inhibitorPrescription onlyKisqali (ribociclib) is a medication used to treat certain types of breast cancer, specifically hormone receptor–positive, human epidermal growth factor 2-negative (HR+, HER2-) breast cancer. It belongs to a drug class called CDK4/6 inhibitors, which help slow or stop cancer cells from growing. You typically take a tablet by mouth once a day for 21 days, then take 7 days off, repeating this 28-day cycle. It’s often taken together with other hormone treatments, like aromatase inhibitors or fulvestrant. Common side effects include feeling tired, nausea, and low white blood cell counts, which can make it easier to get infections.
Summary for Cyclin-dependent kinase (CDK) inhibitorPrescription onlyIbrance (palbociclib) is a capsule or tablet you take by mouth to treat certain types of breast cancer, specifically hormone receptor-positive, human epidermal growth factor 2-negative (HR+, HER2‑) advanced or metastatic breast cancer. It works by blocking specific proteins called CDK4/6 to help slow down the growth of cancer cells. You usually take it once a day for 21 days, and then don’t take it for 7 days, repeating this cycle every 28 days. Ibrance (palbociclib) is also used with other medications like an aromatase inhibitor, fulvestrant, or inavolisib. Side effects include low white blood cell counts, infections, nausea, and tiredness.
Indications of Kisqali vs. Ibrance
Indications for•Early breast cancer (HR+, HER2-), used with an aromatase inhibitor in adults at high risk of the cancer coming back•Advanced or metastatic breast cancer (HR+, HER2-), used with•An aromatase inhibitor as the first hormone-based treatment OR•Fulvestrant either as the first treatment or after the cancer has stopped responding to hormone-based treatmentIndications for•Advanced or metastatic breast cancer (HR+, HER2-), used with•An aromatase inhibitor as the first hormone-based treatment OR•Fulvestrant after the cancer has stopped responding to hormone-based treatment•Advanced or metastatic breast cancer (HR+, HER2-) with a PIK3CA mutation, used with inavolisib and fulvestrant after the cancer has come back following hormone therapyPros and Cons of Kisqali vs. Ibrance
Pros and Const for Cyclin-dependent kinase (CDK) inhibitorPros•Taken by mouth once a day•A first-choice treatment option for HR+, HER2- breast cancer•Can be taken with or without foodCons•Common side effects include nausea, tiredness, and headache•Requires regular blood tests to monitor for side effects•Interacts with many medicationsPros and Const for Cyclin-dependent kinase (CDK) inhibitorPros•Oral pill taken at home•Recommended treatment option for advanced or metastatic breast cancer (HR+, HER2-)•Helps you live longer without the cancer getting worse compared to hormone therapy aloneCons•Raises your risk for infections, some of which can be serious•Requires regular blood tests to check white blood cell count•Not safe to take while pregnant or breastfeedingCommon Side Effects of Kisqali vs. Ibrance
Common Side Effects forEarly breast cancer
•Lower white blood cell counts (up to 97%)•Lower red blood cell counts (47%)•Higher liver enzymes (up to 45%)•Infections (37%)•Higher creatinine levels (33%)•Lower platelets (28%)•Headache (23%)•Nausea (23%)•Tiredness (22%)Advanced or metastatic breast cancer
•Lower white blood cell counts (up to 95%)•Lower red blood cell counts (68%)•Higher liver enzymes (up to 55%)•Nausea (47%)•Infections (47%)•Higher creatinine levels (42%)•Tiredness (35%)•Low red blood cell count•Lower appetite•Dizziness•Trouble sleeping•Trouble breathing•Swollen or sore mouth•Stomach pain•Fever•Pain or swelling in arms or legs•Liver problems•Lower platelets (34%)•Diarrhea (33%)•Vomiting (29%)•Headache (27%)•Constipation (25%)•Hair loss (25%)•Cough (24%)•Rash (24%)•Back pain (24%)•Lower blood sugar (20%)Note: Side effects listed above were reported in studies where people took Kisqali (ribociclib) with another hormone medication.
Common Side Effects forIbrance (palbociclib) with letrozole:
•Low white blood cell count (up to 80%)•Infections (60%)•Tiredness (37%)•Nausea (35%)•Hair loss (33%)•Mouth sores (30%)•Diarrhea (26%)•Anemia (24%)Ibrance (palbociclib) with fulvestrant:
•Low white blood cell count (up to 83%)•Infections (47%)•Tiredness (41%)•Nausea (34%)•Anemia (30%)•Mouth sores (28%)•Diarrhea (24%)•Low platelet count (23%)Ibrance (palbociclib) with inavolisib and fulvestrant:
•Mouth sores (51%)•Diarrhea (48%)•Tiredness (38%)•Nausea (28%)•Rash (26%)•Reduced appetite (24%)•COVID-19 infection (23%)•Headache (22%)Warnings of Kisqali vs. Ibrance
Common Side Effects for•Lung problems•Severe skin reactions•Heart rhythm problem (QT prolongation)•Liver problems•Low white blood cell counts•Harm to unborn babyCommon Side Effects for•Low white blood cell counts•Lung problems•Harm to unborn babyPrices with our coupons for Kisqali vs. Ibrance
Compare other Breast Cancer drugs
Browse medications
View AllResearch prescriptions and over-the-counter medications from A to Z, compare drug prices, and start saving.